A randomized controlled open-label trial for the efficacy and safety of low dose febuxostat and benzbromarone in gout patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019352

Enrollment

Unknown

Registered

2018-11-07

Start date

2016-01-01

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout

Interventions

Group 1:febuxostat 20mg/d p.o. + sodium bicarbonate 1g qd p.o.

Group 2:benzbromarone 25mg qd p.o. + sodium bicarbonate 1g qd p.o.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male patients diagnosed with primary gout based on the 2015 criteria with fasting uric acid exceed 420 µmol/L; 2. Fasting uric acid >420 µmol/L; 3. eGFR=30mL/min; 4. without gout attack in the past two weeks.

Exclusion criteria

Exclusion criteria: 1. serious comorbidity. 2. in need to take any urate-lowing drugs or other medicine affecting the serum uric acid.

Design outcomes

Primary

Measure	Time frame
Target rates;decreasing range of uric acid;	—

Secondary

Measure	Time frame
gout flare;	—

Countries

China

Contacts

Public ContactLi Changgui

the Affiliated Hospital of Qingdao University

changguili@vip.163.com+86 18661808082

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 2, 2026